The Greenlight To Exit Tech… And Pfizer’s Obesity Hopes 7/11/24

11 Jul 2024 · 41 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Fast Money Podcast Summary

Episode Title

The Greenlight To Exit Tech… And Pfizer’s Obesity Hopes (7/11/24) Host: Melissa Lee Panelists: Dan Nathan, Guy Adami, Tim Seymour, Steve Grasso Podcast Description: CNBC's "Fast Money" delivers actionable news for investors, dissecting market trends and financial news.

---

Episode Overview This episode centers around significant market shifts due to falling interest rates, prompted by a lower-than-expected inflation report. It also discusses Pfizer's new developments in the weight-loss drug market and various stock performances, including major tech firms and airlines.

---

Key Topics Discussed

  1. Interest Rate Movements
  2. Falling Yields: Yields dropped to their lowest since March, with the 10-year falling below 4.2%.
  3. Impact on Markets:
  4. Increased hopes for a rate cut are driving rotation from crowded trades (like mega-cap tech) to laggards (small caps, housing, banks).
  5. S&P 500 closed lower despite reaching an all-time high, raising concerns among traders about vulnerability in major stocks.
  1. Rotation in Market Trends
  2. Emerging Trends:
  3. Investors are considering exits from high-flying tech stocks (e.g., NVIDIA down 5.5%, Apple ending a record streak).
  4. A rise in sectors sensitive to interest rates, with homebuilder ETFs jumping over 6%.
  5. Discussion Points:
  6. The panel debated whether this rotation has staying power, with insights on individual stock performances.
  7. Some panelists suggested that profit-taking in tech stocks might be prudent as earnings season approaches.
  1. Pfizer's Weight Loss Drug Trials
  2. New Developments:
  3. Pfizer is advancing trials for its new obesity drug, Danuglipron, after overcoming initial setbacks.
  4. Analysts are cautiously optimistic but await more detailed clinical data.
  5. Market Reaction:
  6. Pfizer's stock is rebounding, with an expectation of increased interest in weight-loss treatments.
  1. Airline Performance
  2. Delta Airlines:
  3. Despite reporting record revenues, Delta shares dropped 4% due to disappointing earnings guidance and rising costs.
  4. Discussion included comparisons to other airlines and the overall industry outlook.
  1. Broader Economic Indicators
  2. Inflation and Economic Health:
  3. The panel highlighted ongoing inflation concerns, even with recent data suggesting trends toward stabilization.
  4. Conversation included implications for Federal Reserve policy decisions and their market effects.

---

Key Takeaways

Market Sentiment

  • Caution in Tech: Recent price movements in mega-cap stocks suggest a potential market correction, prompting discussions on profit-taking.
  • Interest Rate Expectations: The likelihood of a Fed rate cut in September is influencing market behavior, especially in interest-sensitive sectors.

Pfizer's Positioning

  • Competitive Landscape: Pfizer's late entry into the obesity drug market raises questions about its ability to capture market share dominated by other players like Eli Lilly and Novo Nordisk.

Airline Industry Insights

  • Pressure on Airlines: Although Delta remains a strong player, challenges from rising costs and changing consumer demand are impacting stock performance.

---

Conclusion The episode captures a transformative moment in the market, driven by interest rate movements and sector rotations. It emphasizes the need for investors to remain vigilant, especially as earnings season unfolds, and the potential risks associated with high valuations in tech stocks. The ongoing developments in the pharmaceutical sector, particularly with Pfizer, add another layer of complexity for investors seeking growth opportunities.

---

Disclaimer: The opinions expressed in this podcast do not reflect the views of CNBC or its affiliates and should not be treated as investment advice.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:03Live from the Nasdaq market site in the heart of New York City's Times Square this is fast Here's what's on tap tonight. Heading for the exit as rates tumble today. Investors who have flooded into the Mag7 software stock and even the obesity names, they all race for the door. We'll break down where the herd migrated and if this is a move that has staying power. Plus, hitting the brakes, shares of Tesla tumbling on reports of companies delaying the much-hyped RoboTaxi event. The details and the fallout coming up. And later, Delta's turbulent day, despite reporting record earnings, a crypto darling announcing a big stock split.

0:36And the NFL commish weighs in on giving private equity a seat at the table. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Dan Nathan, Guy Dami, Tim Seymour, and Steve Grasso. And we start off with a great rate retreat. Yields dropping to their lowest levels since March as a softer than expected inflation report boosted hopes for a rate cut in September. The 10-year falling below 4.2 percent, while the two-year was under 4.5 percent at its low. That after the consumer price index fell a tenth of a percent from May to June. The first month-over-month decline since April 2020.

1:10Markets now seeing a 90-plus percent chance of a rate cut by September, sharply higher than just a day ago. The move lower in yields, understandably boosting rate-sensitive sectors like housing, banks, retail, biotech, small caps. The homebuilder ETF jumping more than 6 percent, its best day since November 2022. The Russell 2000 hitting its highest level since March. All that made sense. On the other hand, the recently red-hot mega-cap tech stocks did not catch a bid from the drop in rates. AI darling NVIDIA dropping 5.5%. Apple snapping a seven-day streak of record closes. So is this kind of green light for investors to exit what have been very crowded, profitable trades and rotate into some of the laggards in the market, Guy?

1:55Well, when you see price action like this, the answer is yes. Yes. And again, you know, we had brought up March 8th a bunch of times in terms of NVIDIA specifically. You subsequently brought up Broadcom. I mean, that March 8th reversal in NVIDIA actually worked. And by middle of April, the stock was down 24 percent. Individual stock wise. So the same thing on June 20th in that name. And by the way, it's never recovered. But when you see a move like this, the magnitude of the reversal in the S &P, which, by the way, today made an all time high and effectively closed on the low. That's got to give you some pause, I think, for the overall broader market.

2:27So I do think those big names are vulnerable for the first time in a while. And for the first time in a while, you're starting to see technicals that suggest that the broader market might be in for a bit of a sell off. I know what you did last summer. Remember that one? No. Is that a movie? Yeah. So last summer, you know, heading into Q2 earnings season, we saw similar sort of sentiment, you know, really positive in a lot of these big names. Now, granted, they're all up a lot more year over year since then. And to Guy's point, you know, the NASDAQ and the S &P were making new highs today before these huge reversals.

3:01And so when you think about just how investors are positioned, it's not too different as we go into Q2 earnings season. It might be just as good as it gets right now, especially if you see any sort of deceleration for Q3 or the back half of this year as it relates to guidance. And so it probably makes some sense to kind of take some profits here, roll into some of these other things. And I'll just say this. It's really interesting that the S &P closed down less than 1%. We saw how the equal weight S &P traded. And I think we've just got to mention the Russell 2000 if you look at the performance there.

3:33So a clear rotation. But at some point, if you start getting softer economic data, OK, and we start seeing some guidance from some of these consumer led companies, I think the correlations are going to go much higher. And the last thing I'll just say is the fact that the VIX was unchanged today tells you that there's not a lot of fear as it relates to the broad market. Right. Grasso, this is sort of what you want to happen ahead of earnings season, right? I mean, you want sort of a little bit of air to come out of the tire, so to speak, of the hotter trades before we get, you know, results from NVIDIA and Microsoft.

4:05Yeah, you always want a better entry point. I think, you know, if you go back, the IWM's outperformance today over the NASDAQ or the S &P, it's the biggest outperformance dating back to November or so 2020. So this is not an insignificant event. It's does this last longer than a day or two. So the market wants to believe that we could usher into those smaller cap names. The problem is the smaller cap names need a lower rate environment. this is the first time that the market seems to believe that the Fed is going to cut rates really in the near term versus something where they say, okay, we're leaning more dovish at this point.

4:54So September, I still think that they're behind the curve. They should have been cutting before, but I think September, as you mentioned, 90 % odds. And I think they probably cut again a couple of more times this year. Having said that, let's see if this lasts longer than two or three days, because I have a feeling money will rush right back into those mega cap names again. I guess the question really is, Tim, you know, now that we are 90 percent sure that this is actually going to happen in September. And by the way, we're also getting some comments from Austin Goolsbee, who's saying this is what a path to two percent inflation looks like.

5:30This is exactly what you want to have here. Do we start trading for a lower interest rate environment? And what does that mean? Does it mean that the tech stocks can't rally the way they have? Does it mean that we won't see the torrid advances that we've already put in the books? Well, I think Austin Goolsbee's thought we had 2 % inflation for a long time. I mean, I'd listen to Powell this week, though, when he did say if we get more good data, that gives us more confidence that we're moving closer to 2%. There's no way they're going before September. They will go in September based upon the data we have today.

6:05But I think a lot of the reaction today is just a result of momentum trades gone wild. And yeah, I mean, we can come up with all the stats that are extraordinary, which is a 720 basis point outperformance by small caps to the semis. So the worst performer against the best performer. And you can see it, you can see it in the dollar, you can see it in gold, you can see it in rates, you can see it in the end. You can see it in places where we've had extreme positioning. And I think a dynamic also that just at least supports the view that the Fed, certainly their most aggressive days are behind us.

6:39But I'm not chasing small caps here. I'm not chasing housing stocks here. Housing stocks, which if anything, to me, we talk about this every day. So I think once you get people back into the market, prices get marked down. I think you actually have things that, you know, prints that hit the tape that show that some of these asset classes are going to be under pressure. This was a day when the biggest victims of Hire for Longer rallied as a sigh of relief. And that included some of the restaurant stocks and the apparel stocks. Look at the move in retail overall. I don't think that changes the story for the consumer.

7:12I don't think this changes the story for where most of the earnings growth is coming from the S &P. So yeah, I think it's very healthy for the market. It's nice to see it. Let's see what banks do tomorrow. We have finally an earnings season to kind of digest this. But I just think this is a result of some extreme positioning. And I think Dan referenced the VIX. I think it's right. And I think I'm not sure I'd be running out the door on mega cap tech stocks today. I mean, you almost might want to even throw in banks into the extreme positioning when it comes to the move they've seen lately going into this earning season where expectations are extremely high that they're going to declare an inflection point for NII in the second quarter.

7:53And Basel III and the seemingly the less restrictive policies are going to be supportive of these banks. People have been talking about that for a while. I mean, Austin Goolsbee, I'm sure he's a lovely guy, but he clearly doesn't buy car insurance because that was up 19.5%. I mean, he hasn't gone to the hospital, thank God, because that's only up 7%. So all the inflationary things are still there. That's why people are so exorcised at what's going on. And that's why, again, the stock market's not the economy. And now it's 39 months in a row that inflation in the form of CPI has been 3 % or greater.

8:23So he's going to be right at some point. Good for him. With that said, I mean, price action does matter. And again, as I mentioned, you saw something on June 20th you haven't seen in a while. And you clearly saw something today. And I'll throw this in the mix because why not? If you can close tomorrow below, I want to say the level is 55, 64 or so in the S &P, which is not far away. And then not only do you have an outside day, you have an outside week in the S &P to the downside, which is something we haven't seen in quite some time. Yeah. So I found the price action very curious in some of these largest names today.

8:55Definitely a bit overdone in the very near term. But the fact that some of these names closed on the dead lows, NVIDIA is one of them. Tesla is another. It makes you believe that there's probably going to be some follow through. And, you know, I just went back and I looked at the Nasdaq 100 and I think about the performance off of the COVID lows. That was March of 2020. And I think about it. It's like the Nasdaq 100 was up 140 percent. Then it sold off as soon as the Fed signaled they were going to start raising interest rates. Now, no one thought that they were going to be raising as far as they did up 550 basis points or whatever.

9:30And then we sold off 35 percent to the lows in 2022. Right. Then we had this huge rally since then. And so when you think about how much further we are along, You think about how much multiple expansion is in that. You say to yourself, listen, we could be setting up now that rates are going lower. We've seen the data is that stocks act pretty well in that period between the last hike and the first cut. I think on average, going back 50 years or so, when the Fed starts cutting rates, I think there's a decline 12 months out on average of about 10 percent or so. And some of those are bigger than they were, let's say, in the 80s and the 70s of late.

10:08So it makes sense when you hear Mike Wilson saying a 10 percent correction. We're increasingly hearing that, especially in the third quarter, that it's going to be volatile partly because of the election, partly just because of the timing in the rate cycle. We've also, you know, we're talking about inflation, the path to 2 percent. Part of the path, though, is the inflation side of it. That's what Powell had, you know, obviously addressed in his testimony in front of the House and in front of the Senate, Steve. And that is, you know, there are two risks here. the risk for inflation, which seems to be abating at this point, especially with the CPI print, but the the unemployment risk, which is still not necessarily we can't really declare that, you know, abating right now at all.

10:49Yeah, you know, as soon as the labor market starts to get tapped, that's what's going to make make Powell really start to put his foot on the gas as far as cuts are concerned. And that's what they want to stay away from. They want to keep that soft landing intact. Those long and variable lags, I think, are really starting to set in. A third of CPI are housing costs. So you really need to see that. And I think that the Fed is actually to blame partially for that because rates are staying high. Owner's equivalent rent staying high, rent staying high. So a third of that number is really based on where rates are right now.

11:31Seasonality, Melissa, with July, as we've all stated, the first two weeks are the most bullish time of the year for the markets. But after that, because about$9 billion gets put to work, most of it's passively in the markets. After that, it gets a little bit easier for the market to sell off. You have seasonality working against you if you're a bull in August, September, and October. October. So you could see a pullback within the markets. Yeah. And Tim, you know, when you take a look at some of the big cap tech trades, it's sort of I don't want to say dangerous. I don't want to, you know, make any judgments here.

12:09But the price act, the expectations being so high and the price action, just the technicals of this trade not being very good. It's a terrible combination here. It's not great. And we know that three hundred forty billion in CapEx is spent by the hyperscalers in AI, and we don't know what it really leads to yet. So yeah, look, let's watch. I think today was a very, very important day for markets. We haven't seen anything like this in a long time. All right, let's get more on rates and inflation with Priya Misra, fixed income portfolio manager at J.P. Morgan Asset Management. Priya, great to have you with us.

12:43Welcome to Fast Money. Thanks for having me. Has your outlook changed at all based on today's print? So it hasn't changed, but like Chair Powell said, we need more confidence. The Fed's looking for more confidence? Well, we have more confidence. So the Fed is about to start to cut rates. We expect the first cut in September and a series of cuts after that. I think we're going to stop talking about when do they start? Is it September, November, July came up today? Two, how much are they going to cut? And, you know, are these soft landing cuts? Soft landing cuts are very, very rare. You know, the only time we've really seen it is in 95, where they cut only 75 basis points.

13:18The market's pricing in cuts all the way to three and a half. I think even in a soft landing, they can cut to 3%. And what if that labor market does continue to weaken? Then they are cutting a lot more. Do they cut quickly enough? I think that's what the market's grappling with. But I think the fixed income market heard that report, said the Fed's going to start to cut. Interest rates fell. And I think that's the start. Now we start to price in these rate cuts and the totality of that easing cycle. Are equity valuations telling you anything about the fixed income market or vice versa? And just curious, because again, we know that valuations are not a good timing tool, but it seems that they're kind of extreme in a handful of names that represent a disproportionate amount of the earnings growth.

13:58And if we were to see deceleration, I think you'll see multiples come in. So I think it's fascinating. Unlike the equity market where the concentration is so high, in the fixed income market, I would argue there's value across the board. It's because a lot of the fixed income investors have been out of the fixed income market. Because you had negative real rates, you know, interest rates were zero for a very long period of time. Then when we had these rate increases, there was this fear that inflation might resurface, might be sticky. The Fed still might hike. I think all that money has been, you know, sitting on the sidelines.

14:29So we see value in investment rate corporate, in high yield and securitized credit. So I would say when I look at the equity markets, actually interesting tells me positioning. Positioning is highly concentrated in these few sectors. And I look at the fixed income market and I see a sea of opportunities as that as we start to realize that these all in yields of five percent, six percent, we're not getting that as the Fed starts to cut rates. I think you'll see that, you know, investors starting to look for value across the board. Priya, when we got to March, we reached the longest inversion since they started counting, you know, inversions.

15:01Right. I think it was longer than the 78 to 80 period. So we're in July now. I think we're what, 28 or so basis points. But it appears as though we're going to re-steepen. I think we got down to 13 basis points earlier this year. What does it mean? Is it a good thing or historically it has not been such a great thing for equity markets? So I think inverted yield curves are weird. And the market's been, you know, dealing with that, which is why your question is valid. I think the question is how much can we steepen? As long as we start to un-invert or dis-invert or get to more normal levels, the front end really now is the Fed starts to cut rates and we start to think, well, they can cut all the way to 3%.

15:40The Fed's own dot plot suggests 275. If they cut that much, that front end has a lot more room to fall. The long end, not as much. That's a normal yield curve. That's good for banks. I think, you know, you can start to look at every other market and say, which areas benefit from a steep yield curve? I think a steep yield curve is good, but we have to be careful. If it's steepening too much, that's a sign of a recession. That's bad. So I would say small steepening is actually good for certain sectors. You start to steepen a lot more. That means the market's getting the rates. Market's telling you that, you know, something's not that good.

16:12This is a sinister weakening. Recession's always nonlinear. Every recession starts out looking like a soft landing. I think that's the concern if it steepens too much. I don't think at a, you know, 50 basis point, two stents, that's concerning for any market. And just quickly, Perea, you mentioned the market's starting to price in now the totality of the cuts. We know that they are going to start. What are you telling clients in terms of when that happens? Do you think we're going to price that in very quickly? Are we going to see that being priced into the rates market very quickly? I think we're sort of near end of cycle.

16:44But the end of cycle can last for a while. And can we, we're in a soft landing right now. Can the soft landing persist? So what we're telling clients is we're in a soft landing right now. Think about, you know, locking in these yields. The Fed's likely to cut to three and a half or maybe 3%. If things slow down faster, you want to hedge your risk assets. And that's when you want duration risk. The only, I think, correlations are coming back. We haven't had any stock bond correlations for a long time. They're back because the Fed's telling you the inflation fear is on the side. And now they're willing to respond if things slow down.

17:18So, you know, I think we, you know, to your question, will we price it in quickly? You know, we have retail sales next week. If that's weak, we'll price it in very quickly. The market's going to start to say, well, why can't the Fed cut three times this year? Why can't they cut 50 basis points in December? So depending on the data surprises and end of cycles can turn very quickly, I think the market can be really fast. If the data remains resilient, earnings season is good and the consumer continues to spend, I think then rates market is probably fair. Priya, thank you. Nice to see you. Priya Misra.

17:50Tim, that means that the next few prints, retail sales, jobs, etc., they will be key in terms of how investors perceive this market. Yeah, and I think we go from a case where inflation with the Fed's dual mandate being inflation and full employment, it's clearly been a focus on inflation. And we'll just see where employment comes in. But you get to a place where we start to worry about growth and you could still have sticky inflation and full employment could really suffer. So yes, I totally agree. I mean, Priya's point is fascinating in that we've, you know, we could be mid-cycle, depending on who we ask who comes on our show, we could be early cycle to mid-cycle, but it could very quickly move to late cycle.

18:31And that's what's been so interesting about this period that people have universally gotten wrong in terms of the impact of one of the most aggressive Fed hiking periods in history and what it would do to the consumer and what it would do to spending. I think that is what will happen. I think we will go from a place where we were surprised by the duration of this market and the duration, though, really of the economy and a soft landing to maybe not so soft. And I think the market's disposition will be to be very fearful of prints in retail sales and the labor market that show weakness. All right.

19:02We are less than 90 minutes away from President Biden's first press conference since last month's debate. He takes the stage as more Democratic members of Congress call for the president to bow out of the race. Emily Wilkins has got the very latest on this. Emily. Hey, Melissa. Yeah, Biden's campaign to keep the confidence of members of his own party. It's not going very well. Just in the past few hours, another four congressional Democrats have spoken up publicly saying that Biden should withdraw. And others have registered serious concerns with Biden's ability to continue. So the most recent four, Congressman Brad Schneider, Ed Case, Greg Stanton, and Hillary Scholten.

19:38Now, Scholten has one of the more difficult re-elections, and she said in a statement that, quote, with the challenges facing our country in 2025 and beyond, it is essential that we have the strongest possible candidate leading the top of the ticket, not just to win, but to govern. Now, this brings the total number of lawmakers who are publicly calling on Biden to withdraw up to 14, but many more have voiced serious concerns in private and even congressional leaders have so far kept most of their statements on Biden big as they've been listening to rank and file members this week and are now trying to take everything they've heard and relay that to Biden's team.

20:17Biden's top advisors met with senators for more than an hour today, laying out their strategy for winning in November. Senator Richard Blumenthal told us after he left that meeting that Biden's team did not fully alleviate his concerns. Some of my concerns are laid. Some others have been deepened. I need more of the kind of analytics that show the path to success. Lawmakers told me that they will be watching Biden's press conference this evening, but several stressed to me today that it is not just about having a one good public appearance, but having a long ranging plan both to beat Trump come November and gain the courage and confidence of the American people back.

21:00Melissa? There are also increasing reports, Emily, that, you know, they're they're sort of polling Vice President Harris and to see if she's going to sack up better against Trump. I mean, what are you hearing in terms of the various alternate candidates, Vice President Harris, of course, but also others that that may fill out the ticket? Well, Melissa, NBC has confirmed that the Biden campaign is looking at Harris and how she would poll. And to a certain extent, Harris would have an advantage because she would really be able to immediately tap into all of that infrastructure, all of the fundraising that the Biden campaign has.

21:34And so that is a major advantage for her. She's also pretty well known at this point, having been vice president for the last four years. But at the same point, a lot of members who I'm seeing and a lot of them, you know, they like Kamala Harris, but they're not willing to say, OK, she should indeed be the nominee. A lot of them seem to be leaving it open. Of course, there are a number of other very strong contesters who could jump into a potential race. You have a number of governors from swing states who really know how to repeal to Republican and independent voters, which is going to be absolutely critical.

22:06And I think at this point, everyone is just kind of focused on Biden himself. And then, of course, the question is what happens next if he does decide to withdraw? Emily, thank you. Emily Wilkins on this developing story here. The conventional thinking is that a Trump win, a Trump administration would be better for the markets. So, Steve Grasso, if there is a change in the Democratic ticket, which could then strengthen the down ballot elections as well, what does that do in your view? Well, if there's an idea that Trump has a better chance of winning now and then down ballot, the real choice is do you have gridlock government or do you have one party come in with a wave?

22:51And if, to your point, if Trump can perform and help the down ballot candidates perform, then the Republicans take the Senate. And if they could hold the House, which seems seemed unlikely a couple of weeks ago and seems likely, then Republicans will have total control and then you don't see those tax cuts roll off in the next year and a half or so. So that is deemed as positive to the market. So you don't really know who's, and the only candidate, Melissa, that can really come in is VP Harris. That's the only way that you can get that money that President Biden has built up so far to go straight to her.

23:30Newsom would not get it. No other candidate would be entitled to it. Coming up, a Tesla snap against 11-day winning streak in a very big way. The latest headlines have had investors unplugging from that one next. And from wheels to wings, Delta also sinking in today's session. The turbulence in their earnings report that had shares heading lower. Don't go anywhere. Fast Money is back in tune.

Read the full transcript

23:57Welcome back to Fast Money. Delta shares down 4 % today despite posting record revenue. As the airline saw earnings drop 30 % in the latest quarter, the company also gave disappointing guidance amid higher costs and discounted fares. Phil LeBeau spoke with Delta CEO Ed Bastian today, and he says the industry is overcorrecting itself. He expects unit revenues for the company will turn positive in September. And Tim, you know, Delta is the best of them. They've got more premium seating. They make a lot off their loyalty program. And this is what happened to them. Yeah, well, again, airlines, the greatest trading stocks in the market, and sometimes you dance by the door with Delta after a 75 % move from October through to the highs we had, I don't know, in May at some point, the stocks pulled back intraday.

24:43I think it was about a 20 % pullback off those numbers. It was the third quarter guide that was terrible. And it gets back to what we worry about with airlines. When the getting starts to get good, capacity increases and inefficiencies go down, margins go down. And at some point, it's a lot harder to change that dynamic. That's exactly what we got here. There's also a new post-pandemic dynamic just in terms of seasonality. Second quarter, a lot better than third quarter. And that's also what we heard. So I think, yes, best of the group gives you this kind of guide. It puts pressure on the space.

25:15I think you're going to get Delta a little bit lower. But at some point you're buying this one because it is the best airline of the bunch and the margins are fine. The balance sheet's great. Southwest and American already guided lower, Steve. So are they, I don't want to say safe, but has some of this been priced in? Yeah, you want to get a better, you want to let the first one who reports, take it on the chin, so to speak, and then the rest have a better entry point when they report. But to Tim's point, they make more than 50%, as you said, on their loyalty program and on premium seats. Same thing roughly with UAL.

25:57And when you look at a premium airlines, you want to go to the international travel because when you came out of the pandemic, they beefed up. They bought a lot more planes. They had to keep up with demand. They bought bigger planes. They have better seating. So there's a whole thesis behind why they thought they were going to be successful. Now the market got a little bit ahead of itself. I would stick with the international facing airlines versus the domestic ones, because I think those are going to be the ones that recover quicker than the domestic players. All right. Coming up, Pfizer positivity, the farmer giant higher after encouraging trial data on its weight loss pill, what it's mean for the sector.

26:38With Mizzou host Jared Holes, that's next, and NFL Commissioner Roger Goodell in the hot seat, what he thinks about media rights, deals, and much more. Back in two.

26:54Welcome back to Fast Money. Another contender in the weight loss drug battle may be emerging. Pfizer advancing early trials for its once daily pill. The pharma giant telling investors it reworked its trials following last year's setback. Pfizer shares closing up a percent, but off the highs of the day. Let's bring in Jared Holes, Mizuho's healthcare strategist. Jared, great to see you. How good is this news? I mean, this drug had been, I don't want to say left for dead, but I mean, there's real disappointment surrounding that drug when it was in phase 2B and it had to be put back into phase 1.

27:26And here we are now. So how big of a development is this? Great to see you, too. I think it's a small development. I agree with everything you said. I think they're kind of resuscitating this program in order to still be in the game. But it just doesn't sound like there's that much substance here until they give everyone more information about the clinical data itself and then which dose they're going to bring forward. And then over the next six months, it appears like the company's strategies kind of figure out the dosing they're going to use and then move that forward in a bigger phase two, phase three trial.

28:08So I still think they're a long ways away. It's a better outcome than shelving the program in total. But I'm just not sure it's legitimate yet. The drug, which is called Danuglipron, if I'm saying that correctly, they say that to date they've treated more than 1 ,400 patients with this and there are no serious safety concerns. Can we then infer that the profile that they had before where they had a lot of nausea, a lot of vomiting, and that's why they sort of shelved the program temporarily, that that's abated, that they figured a way out? Yeah, they must have solved something here. I mean, when you go through the press release and you dig deeper here, I think maybe the biggest disparity between what they said today and what they've said in the past is that they're going to switch this from a twice a day pill to once a day.

29:06And maybe just that very factor and a lower dose is leading to less side effect. I think that makes a lot of sense. But what they're also saying is that they're working on some sort of modified release, which we don't exactly know what that means either in this sense. But there's something about the way that the drug interacts with the body over time during the course of the day that probably makes it safer. So we'll see. But yeah, it's obviously, you know, more inspiring today than it has been. Hey, Jared, it's Tim. Go Browns, by the way. And I guess the way the market responded today is ultimately how you are assessing what this headline is.

29:49So if you look at the stock and as traders, we can see that Pfizer and you're not a trader, but as a trader, I can see that the stock is now above the 200 day after a horrendous period. It's done some basing. there's some dynamics with the company. Let's talk about the bigger picture, not Danu. Let's talk about whether there is decent risk reward in this stock and where, at least in terms of the current pipeline, you feel like there's the most reason for optimism. Hey, Tim. Yeah. I know you've liked this one for a while. I agree. I think it's rebasing here. I think the main reason is because what we kind of saw on the back of the first quarter earnings was that the the numbers that Pfizer put up were better than its initial guidance.

30:34And so I think the street kind of extrapolated that. And what they did is they moved the earnings estimates forward a little bit or higher rather. And that's given people more confidence that you're going to get potential beats and raises on the earnings line through the course of this year and maybe next year. And so a lot of the buy side, I think the view now is that estimates are too low, guidance is too conservative and some of the cost cutting measures and drug launches that they have in concert are leading to better earnings. So instead of the original guidance that they gave, maybe there's a little bit of upside this year and next year.

31:11And so I think that's kind of put a floor in the stock, you know, the$25 to$27 range, and it really hasn't gotten lower than that. So I agree. It's probably rebasing. Today's news helps it fundamentally. But if you're just looking at this as far as like a PE multiple and a higher earnings number, I think that's what's really helping it. Jared, good to see you. Thank you. Great to see you. Thank you. Jared Holes. All right, Guy. I guess he couldn't make it in, Jared. You had something better to do. Maybe he could be in another city or another country. Yeah, it's a fair point. He dropped in to say hi.

31:45Look at the IBB. Throw up a chart. Two-year high. I mean, four stocks are 32%. We talk about them Regeneron, Gilead, Vertex. I think Amgen's in there as well. That's having a day. And if money starts to flow out of these big cap tech names, one of the places it's going to wind up is in biotech. So I think you stay with this trade here, especially Gilead, which Raymond James, I think yesterday or two days ago, just put a$93 price target. And there is an argument that Gilead should get some credit for its weight loss drug because if Pfizer's getting some, Gilead should get some too. But what we saw today, going back to the top of the show, Grasso, is money flowing out of the most crowded trades.

32:18That's also Eli Lilly and Novo Nordisk. And we So we're seeing this within the sector a little bit here. Yeah, I mean, they really have to, they're the NVIDIAs, right? The Lilly and the Novo are the NVIDIAs of the biotech space. I agree, you should see some money come out and use those as cash machines. But the problem is, they're the ones who've cornered the market. I think it's ironic, though, when you look at Pfizer's chart, it's given up all of the vaccine from COVID benefits. So you look at the chart and you go back five years, it's trading right around that March 2020 low in the stock. So they're looking to replace that income.

32:59And a lot of people are looking for an alternative to giving themselves a shot and looking to take an oral pill. And it's not a bad entry point for Pfizer, but they're definitely late. They're definitely lagging. Lilly and Novo are the places where people want to be. Coming up, a few earnings reports from this morning catching our attention. how our traders are handling the move in Pepsi, as well as Conagra. That's next. And sports streaming coming into focus at the Sun Valley Conference. What NFL Commissioner Roger Goodell had to say about rights, partnerships, and private equity. Much more Fast Money in two.

33:39Welcome back to Fast Money. Two consumer staple names on the move after reporting results this morning. Pepsi, posting a revenue miss and narrowing its revenue outlook for the full year. Shares had been down more than 3 percent early in the day, but finished in the green. ConAgra brands also missing on the top line and projecting lower profit for the year as weak demand continue to weigh on sales. Both stocks in the red so far this year. What do these stocks have in common? People don't want to pay high prices anymore. They can't raise prices anymore. Volumes are coming down, Tim. There's a pushback across income levels, according to Pepsi, too.

34:13So it's not just low end. Yeah. No, I just I don't need Fritos right now. And I do think you have a case where at some point things get interesting. The valuation has come down substantially, but they also CPG and certain parts of the snack space were also in that sweet spot that some of discretionary was during COVID. and you saw Pepsi behave also with that pricing power. They're almost boasting their ability to pass on prices. And at this point, I think they've got multiple quarters of headwinds on that. So I think you're going to get it lower. And again, if you look at a five-year chart, you start to assess some of those trends.

34:50But you ultimately assess the valuation from where we were on a pre-COVID basis. And I think you could trade down one or two turns. I like the story. I think both Staples and CPG are going to get interesting. It's just not yet. Steve? Yeah, wasn't this the Ozempic effect, though, too, when we first started talking about weakness here? And then the next level was, to your point, shrinkflation. When you look at the charts, Pepsi, I could find, I could maybe create some support in the name. If I look at both of these charts, nothing makes me excited about them. But they are at levels where, in theory, they should bounce.

35:28So maybe, as Tim said, maybe you can get it a little bit lower. but they look like they are right where they should be bouncing on the chart. You think it looks interesting. 160, Pepsi, 160 is a big level. I think to Steve's point, I'm with more in Tim's camp, though. And organic growth has always been sort of code word for we're going to pass our inflation cost to you and you're going to suck it up and take it. Now they can't do it. To your other point, organic growth was 1.9 percent, well short of street expectations, and revenue was a miss. So I think this is the beginning of something, not necessarily the end.

36:01Do not miss Jim Cramer's exclusive interview with the ConAgra CEO Sean Connolly. That is tonight, 6 p.m. Eastern Time on Mad Money. Coming up, sports rights in Sun Valley. Our own Julia Borson sat down with NFL Commissioner Roger Goodell. What he had to say about the future of sports streaming and private equities reach into the game. More Fast Money in two.

36:26Welcome back to Fast Money. Sports and media are taking center stage at the Allen & Company Conference. In Sun Valley, Idaho, CNBC's Julia Borsten sat down in an exclusive interview with NFL Commissioner Roger Goodell earlier today. Hey, Julia. Hi, Melissa. That's right. I spoke exclusively with NFL Commissioner Goodell, who made a lot of news. He defended the NFL's decision to appeal its defeat in the class action lawsuit about the distribution of Sunday ticket, saying, quote, we're committed to following the litigation all the way. And I asked him why the NFL added yet another streaming partner in addition to send a ticket on YouTube and Amazon with Thursday night games to now include Christmas Day games on Netflix.

37:08I think the platforms that we've chosen between Netflix, Amazon, YouTube are great platforms that are going to be around for a long time. And that's why we chose them. We think that they're going to attract better content that includes sports. And we think life sports has never been in a better position. Commissioner Goodell also revealed that they are making progress in their talks to allow private equity investments in NFL teams. He said that they would cap ownership at 10 percent. Melissa, that's a lot lower than the 30 percent that's more typical for P.E. ownership. Yeah, Julia, thank you.

37:46Julia Boorstin, a beautiful Sun Valley, Idaho. She looks like she's in front of a painting. Fantastic. What were you saying about Julia Borsten? How much we admire her, how much we just respect her work. Seriously, we were having that conversation. We literally were just having that conversation. I'm just saying. I threw it out there. I don't know. You want me to trade this? Yes, streaming on. Netflix. So pull up a Netflix chart because we talked about how Netflix is going to get in. Not sports necessarily, but something around sports events, right? Karen Feinemann on Tuesday, if you recall, said she was taking some profits.

38:16Look, she might have top ticked that sucker. And if you go back and look, we traded up to the levels we saw, I think, in the fall of 2021. So Netflix is clear to the plate, but you might have a bit of a double top here, Mel. Yeah, just saying about Netflix, really interesting. So that subscriber number was disappointing when they reported Q1. So you've got to keep a close eye on that. But I think we all agree, you know, the way that that stock filled in that gap to the downside after earnings was pretty powerful. You have to think investors are thinking out a little bit towards the second half of the year.

38:45They're going to move really big into live stuff. And I think that's pretty interesting. All right. Up next, final trades.

39:02Final trade time. Tim Seymour. Break up the Mets, first of all. Nice to see Marcus Stroman as the stopper up in the Bronx. Anyway, EWG, the dollar weaker today. International trades are definitely starting to move. I think today might have been a catalyst. Steve Grasso. The Smurfett Westrock deal closed makes them one of the largest paper and packaging companies. Different symbol, SW, same great potential. Dan Nathan. Yeah, Pfizer. If this thing gets any traction on the GLP-1s, it looks like it's ready to party. Tim's Pfizer. Okay. Be sure to catch CNBC's Fast Money, Melissa Lee, tomorrow, 6 to 9 a.m.

39:47On Squawk Box. I'm on Squawk Box. You're killing it this week. You know what else is killing it this week? Check out Letter M, sister. All right. Thanks for watching Fast. See you on Squawk. Mad Money starts right now.

40:01All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

40:35To view the full Fast Money disclaimer, please visit CNBC.com forward slash Fast Money disclaimer.

From the publisher

Yields dropping to their lowest level in months, as this morning’s inflation report boosted hopes of a rate cut. So is the rate retreat the greenlight for investors to rotate into the laggards? Plus Pfizer’s getting in on the weight loss drug battle. How the pharma giant is moving forward with an obesity pill after encouraging data.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
The Greenlight To Exit Tech… And Pfizer’s Obesity Hopes 7/11/24CNBC's "Fast Money" · 41 min
Listen in VO